Celmatix is a preclinical-stage biotech company focused on ovarian health. The company aims to develop treatments for conditions caused by poor ovarian health.

Celmatix

Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead “pipeline-in-a-pill” AMHR2 program focused on ovarian senescence, and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies. For more information visit www.celmatix.com.

Long Island Angel Network

Topspin Partners

Brainchild Holdings

Richmond Global Ventures

Evotec

Special Situations Life Sciences Innovation Fund

Despite often debilitating symptoms, such conditions are still being treated with hormonal interventions introduced more than 50 years ago. The problem doesn’t stop there. Because the ovary plays a critical role in overall endocrine function, women experience serious health problems when ovarian function fails.

Have you tuned into the latest episode of Boss Ovary? https://lnkd.in/d87q2uUN 

Don't miss this episode with our CEO + Founder Piraye Beim and Aparna (Amy) Divaraniya, PhD, CEO + Founder of Oova!

Learn more about: 
✅ Impact of outdated models: How traditional healthcare models and lack of tailored data, negatively affect women's health outcomes.

✅ Empowerment through data: The benefits of having actionable, personalized health data for women to better advocate for their own health.

✅ Innovations in healthcare: How innovations like Oova's home-based monitoring are transforming healthcare practices to be more inclusive and responsive.

Our CEO Dr. Piraye Beim recently spoke to Flow Space about Rapamycin and how researchers at Columbia University Fertility Center are looking into whether the drug can be used to slow ovarian aging. 

"There’s no data on what the consequence will be of taking a completely healthy individual and putting them on Rapamycin, suppressing their immune system chronically,” explains Beim. 

Check out the full article here:

Are you heading to the Women's Health Innovation Summit in September? Our CEO + Founder, Dr. Piraye Beim,  will be speaking on the panel "Ovarian Health: Unlocking The Future of Holistic Hormone Health" with Ivana Muncie-Vasic, CEO & Founder, Vitra Labs.

This discussion highlights the latest developments and research-to-date around ovarian function. Looking at the hormones that dominate the endocrine system, this panel assesses the broader impact that an understanding of ovarian function would have on extending fertility, delaying menopause, and significantly reducing symptoms such as sweating, heart disease and dementia experienced by women throughout their lifetime.

See you there!

A study led by researchers at  Weill Cornell Medicine show changes in the brain during menopause using PET imaging technology: https://lnkd.in/d2PBRMz3

✔ The study, led by researchers at Weill Cornell Medicine, demonstrates the use of PET imaging with an ER-binding tracer, 18F-fluoroestradiol (FES), as a novel method for tracking estrogen activity in the brain, revealing its potential to predict menopause-related cognitive and mood symptoms.

✔ PET scans reveal a significant increase in brain estrogen receptor (ER) density during menopause, with postmenopausal women showing higher ER density than premenopausal women, indicating the brain's compensatory response to declining estrogen levels.

✔ Findings suggest that elevated ER density persists up to a decade after menopause, highlighting a potentially extended window for effective estrogen therapy, which the researchers plan to further investigate for its long-term effects on brain health and symptom relief.

How much do you know about AMH? Anti-Mullerian hormone (AMH) may not be the most widely discussed or well-known hormone in reproductive health, but it is certainly important to understand for a variety of reasons.   

Learn more here and drop your comments below! We'll be doing an AMA "ask me anything" with our Founder & CEO Dr. Piraye Beim soon!  https://lnkd.in/dfd38w3m

Metric
Company Name	Celmatix
Symbol
MSH ID	COM:CELMATIX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	24
Website	celmatix.com
LinkedIn	celmatix
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CELMATIX

Celmatix

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue